Filing Details
- Accession Number:
- 0001104659-23-070804
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-06-13 16:16:17
- Reporting Period:
- 2023-06-09
- Accepted Time:
- 2023-06-13 16:16:17
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1829635 | Transcode Therapeutics Inc. | RNAZ | Pharmaceutical Preparations (2834) | 811065054 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1854161 | Michael Robert Dudley | C/O Transcode Therapeutics, Inc. 6 Liberty Square, #2382 Boston MA 02109 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-06-09 | 19,000 | $2.76 | 912,114 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Footnotes
- Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.675 to $2.85. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.
Billionaire Hedge Funds
